Compare · NVS vs PRPH
NVS vs PRPH
Side-by-side comparison of Novartis AG (NVS) and ProPhase Labs Inc. (PRPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVS and PRPH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $289.20B, about 2586.6x PRPH ($111.8M).
- Over the past year, NVS is up 28.0% and PRPH is down 89.1% - NVS leads by 117.1 points.
- Both names hit the wire about 1 times in the past 4 weeks.
- NVS has more recent analyst coverage (25 ratings vs 3 for PRPH).
- Company
- Novartis AG
- ProPhase Labs Inc.
- Price
- $151.19-0.25%
- $0.36-18.27%
- Market cap
- $289.20B
- $111.8M
- 1M return
- +2.09%
- +0.00%
- 1Y return
- +28.01%
- -89.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 1
- 1
- Recent ratings
- 25
- 3
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
ProPhase Labs Inc.
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States. It offers a range of OTC dietary supplements, including Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support product; and Super ProstaFlow+ a supplement to support prostate and urinary health under the TK Supplements brand. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; and offers SARS-CoV-2 (COVID-19) and COVID-19 viral mutation PCR tests through saliva and nasal swab methods, as well as other respiratory pathogen panel testing services, including Influenza A and B, and others. It serves consumer products companies, as well as large national chain, regional, specialty, and local retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was incorporated in 1989 and is headquartered in Garden City, New York.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
- SEC Form 20-F filed by Novartis AG
Latest PRPH
- SEC Form 10-K filed by ProPhase Labs Inc.
- SEC Form NT 10-Q filed by ProPhase Labs Inc.
- ProPhase Labs Reports Year-End 2025 Results, Highlights Accelerating Settlement Activity and Investment-Ready Crown Medical Collections Platform
- SEC Form NT 10-K filed by ProPhase Labs Inc.
- ProPhase Labs Provides Business Update Highlighting Advancing Crown Medical Collections Activity
- ProPhase Labs Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- ProPhase Labs Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- ProPhase Labs Initiates Potential Sale or Strategic Partnership of BE-Smart™ and Advances Crown Medical Collections Initiative
- Join ProPhase Labs' Exclusive Live Investor Webinar and Q&A Session on February 3rd
- ProPhase Labs Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits